Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to mo… Read more
Market Cap & Net Worth: Biovie Inc (BIVI)
Biovie Inc (NASDAQ:BIVI) has a market capitalization of $10.55 Million ($10.55 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28317 globally and #9450 in its home market, demonstrating a 0.72% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biovie Inc's stock price $1.40 by its total outstanding shares 7537480 (7.54 Million).
Biovie Inc Market Cap History: 2015 to 2026
Biovie Inc's market capitalization history from 2015 to 2026. Data shows change from $1.13 Billion to $10.55 Million (-36.48% CAGR).
Index Memberships
Biovie Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #739 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2369 of 3165 |
Weight: Biovie Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biovie Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biovie Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BIVI by Market Capitalization
Companies near Biovie Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Biovie Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Biovie Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Biovie Inc's market cap moved from $1.13 Billion to $ 10.55 Million, with a yearly change of -36.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.55 Million | +20.69% |
| 2025 | $8.74 Million | -42.00% |
| 2024 | $15.07 Million | -84.13% |
| 2023 | $94.97 Million | -83.78% |
| 2022 | $585.66 Million | +72.67% |
| 2021 | $339.19 Million | -74.02% |
| 2020 | $1.31 Billion | +394.86% |
| 2019 | $263.81 Million | -0.36% |
| 2018 | $264.75 Million | -81.27% |
| 2017 | $1.41 Billion | -49.15% |
| 2016 | $2.78 Billion | +145.83% |
| 2015 | $1.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Biovie Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.55 Million USD |
| MoneyControl | $10.55 Million USD |
| MarketWatch | $10.55 Million USD |
| marketcap.company | $10.55 Million USD |
| Reuters | $10.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.